Novartis AG (NVSEF/NVSEF.PK) Wrap Up:

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division engages in the research, development, manufacture, distribution, and sale of pharmaceuticals in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; and immunology and infectious diseases. The company?s Vaccines and Diagnostics division offers preventive vaccine treatments and diagnostic tools. It provides influenza, meningococcal, pediatric, and traveler vaccines; and blood testing and molecular diagnostics to prevent the spread of infectious diseases. The company?s Sandoz division offers drugs, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; anti-infectives; protein or biotechnology-based products; and biotech manufacturing to other companies on a contract basis. Its Consumer Health division consists of three business units: over-the-counter medicines (OTC), Animal Health, and CIBA Vision. OTC offers over-the-counter self medications. Animal Health provides veterinary products for farm and companion animals. CIBA Vision manufactures contact lenses and lens care products. Novartis AG has strategic alliance with Intercell AG to develop vaccines; CombinatoRx Incorporated to discover anti-cancer combinations; Ablynx NV for the discovery and development of Nanobody-based therapeutics; and MorphoSys AG. It also has research and development collaboration agreements with EpiStem Holdings Plc; Euroscreen S.A.; Nuevolution A/S; and Locus Pharmaceuticals, Inc. The company was founded in 1895 and is headquartered in Basel, Switzerland.